Guidance

Suspension of the Teva marketing authorisation for Levothyroxine 100 microgram tablets

Details of the suspension of the marketing authorisation of Levothyroxine 100 microgram tablets, including MHRA investigations.

Documents

Suspension of the Teva marketing authorisation for Levothyroxine 100 microgram tablets

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This report looks at the circumstances leading up to the suspension of this product, communications about the suspension and the outcome of Medicines and Healthcare products Regulatory Agency (MHRA) investigations immediately following the suspension.

Published 22 April 2013